Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jan-Feb;18(1):69-81.
doi: 10.1097/PPO.0b013e31824671c9.

Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates

Guido Wollmann  1 , Koray Ozduman, Anthony N van den Pol
Affiliations
Review

Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates

Guido Wollmann et al. Cancer J. 2012 Jan-Feb.

Abstract

Twenty years of oncolytic virus development have created a field that is driven by the potential promise of lasting impact on our cancer treatment repertoire. With the field constantly expanding-more than 20 viruses have been recognized as potential oncolytic viruses-new virus candidates continue to emerge even as established viruses reach clinical trials. They all share the defining commonalities of selective replication in tumors, subsequent tumor cell lysis, and dispersion within the tumor. Members from diverse virus classes with distinctly different biologies and host species have been identified. Of these viruses, 15 have been tested on human glioblastoma multiforme. So far, 20 clinical trials have been conducted or initiated using attenuated strains of 7 different oncolytic viruses against glioblastoma multiforme. In this review, we present an overview of viruses that have been developed or considered for glioblastoma multiforme treatment. We outline the principles of tumor targeting and selective viral replication, which include mechanisms of tumor-selective binding, and molecular elements usurping cellular biosynthetic machinery in transformed cells. Results from clinical trials have clearly established the proof of concept and have confirmed the general safety of oncolytic virus application in the brain. The moderate clinical efficacy has not yet matched the promising preclinical lab results; next-generation oncolytic viruses that are either "armed" with therapeutic genes or embedded in a multimodality treatment regimen should enhance the clinical results.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Timeline of oncolytic virus development from glioblastoma therapy
This schematic diagram lists viruses with oncolytic potential based on their first description in preclinical glioma studies starting in 1991. Subsequent major developments within one virus group are included. Viruses are color-coded based on their pathogenic background as human pathogen (orange), human vaccine (yellow), or non-human pathogen (blue).
Figure 2
Figure 2. Mechanisms for selective oncotropism and oncolysis
Molecular mechanisms determining tumor-selective viral infection and replication are grouped schematically based on the cellular compartment of tumor-virus interaction. (I) Extracellular compartment. Some oncolytic viruses (OVs) can exert selective tumor suppression through induction of cytokine production. OV’s can selectively attack vasculature in tumors and tumor-associated matrix proteases can augment virus attack. (II) Tumor cell membrane. Naturally occurring oncotropic viruses bind to tumor-associated surface receptors. OVs can be engineered to enhance tropism to aberrant tumor receptors. (III) Cytosol. Tumors with aberrant signaling cascades (RAS) and antiviral defense (PKR and IFN) can be targeted by a number of OVs. (IV) Nucleus. Activated cell cycle and nucleotide synthesis in transformed cells enable replication of gene-deleted OV mutants. Expression of viral genes can be engineered to be under control of tumor-specific promoters. Abbreviations: IL, interleukin; GM-CSF, Granulocyte-macrophage colony-stimulating factor; LCMV, lymphocytic choriomeningitis virus; PKR, protein kinase R; TK, thymidine kinase, GFAP, glial fibrillary acidic protein.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507. - PubMed
    1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60:166–193. - PMC - PubMed
    1. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15:651–659. - PubMed
    1. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854–856. - PubMed
    1. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373–376. - PubMed

Publication types